Gemina Laboratories Ltd.
GLAB
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -55.02% | -46.65% | -26.85% | 108.75% | -26.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.89% | -54.10% | -14.93% | 27.70% | -6.26% |
| Operating Income | 59.89% | 54.10% | 16.26% | -27.70% | 6.26% |
| Income Before Tax | 61.98% | 57.14% | 11.99% | -77.21% | 26.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 61.98% | 57.14% | 11.99% | -77.21% | 26.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.98% | 57.14% | 11.99% | -77.21% | 26.42% |
| EBIT | 59.89% | 54.10% | 16.26% | -27.70% | 6.26% |
| EBITDA | 56.29% | 54.07% | 15.95% | -28.12% | 13.95% |
| EPS Basic | 63.53% | 59.38% | 15.66% | -78.67% | 27.35% |
| Normalized Basic EPS | 62.26% | 57.63% | 15.38% | -80.85% | 27.40% |
| EPS Diluted | 63.53% | 59.38% | 15.66% | -78.67% | 27.35% |
| Normalized Diluted EPS | 62.26% | 57.63% | 15.38% | -80.85% | 27.40% |
| Average Basic Shares Outstanding | 2.77% | 4.12% | 4.19% | -0.35% | 1.61% |
| Average Diluted Shares Outstanding | 2.77% | 4.12% | 4.19% | -0.35% | 1.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |